NetworkNewsBreaks – Genprex, Inc. (NASDAQ: GNPX)
Post# of 231
(Total Views: 379)
Posted On: 03/24/2020 4:00:59 PM
NetworkNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Strategic Board Appointments of Three Biotechnology and Healthcare Industry Leaders
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced the appointment of three new members to its Board of Directors. The new appointments, which include Brent Longnecker, CEO of Longnecker & Associates, Jose A. Moreno Toscano, CEO of LFB USA Inc, and William R. (“Will”) Wilson, Jr., chairman, president and CEO of Wilson Land & Cattle Co., are designed to strengthen Genprex as it executes on its key clinical programs, continues to build its pipeline, and evaluates future license or corporate partnership agreements. “We are honored to have Brent, Jose and Will join our Board in what we believe is a transformational time for our Company,” Genprex CEO Rodney Varner said in the news release. “Their combined experience in regulatory compliance, business development, clinical trial management, and deal structuring will be invaluable as we continue to develop gene therapy drug candidates and pursue partnerships for our drug candidates. The addition of these outstanding directors, together with our new senior executive hires and a significantly strengthened balance sheet, puts us in an excellent position to execute our plans.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced the appointment of three new members to its Board of Directors. The new appointments, which include Brent Longnecker, CEO of Longnecker & Associates, Jose A. Moreno Toscano, CEO of LFB USA Inc, and William R. (“Will”) Wilson, Jr., chairman, president and CEO of Wilson Land & Cattle Co., are designed to strengthen Genprex as it executes on its key clinical programs, continues to build its pipeline, and evaluates future license or corporate partnership agreements. “We are honored to have Brent, Jose and Will join our Board in what we believe is a transformational time for our Company,” Genprex CEO Rodney Varner said in the news release. “Their combined experience in regulatory compliance, business development, clinical trial management, and deal structuring will be invaluable as we continue to develop gene therapy drug candidates and pursue partnerships for our drug candidates. The addition of these outstanding directors, together with our new senior executive hires and a significantly strengthened balance sheet, puts us in an excellent position to execute our plans.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)